2010

Globalization in the pharmaceutical industry: Where are drugs invented?

November 1, 2010

I’ve just had a paper published in Nature Reviews Drug Discovery, using data from DrugPatentWatch to profile the locations of drug invention for the past decade. The location of drug development is important for two reasons. Firstly, it is important to track the global spread of innovation. Much late stage drug development (e.g. clinical trials) [...]

Read the full article →

Globalization of Pharmaceutical Innovation: Who is leading in drug development?

November 1, 2010

DrugPatentWatch.com publishes research paper profiling trends in global distribution of pharmaceutical innovation

Read the full article →

Bad boards of directors kill more companies than bad management…

October 28, 2010

A side-comment at the Mid Atlantic Biotech conference really got me thinking. One of the panelists mentioned as an aside that she thought that more companies failed due to bad boards than due to bad management (she preferred not to be named). The board of directors is more than a set of advisors to company [...]

Read the full article →

Next DCbiotech meeting: Tuesday November 2nd

October 25, 2010

The next DCbiotech meeting will be at the Marriott Renaissance Washington DC Downtown Hotel on November 2nd 2010. The hotel is at 999 Ninth Street NW, and we’ll be meeting in the Mixx bar from 6:30-8:30pm. To facilitate finding the group, you may want to check out my photo on the about page. Where: Mixx [...]

Read the full article →

Bringing Better Medicines to Market Faster, an Interview with Expert John Avellanet

October 21, 2010

Positive reviews of the book, Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine, have been appearing since the book’s publication earlier this year. The BiotechBlog sat down with author John Avellanet for a discussion of the book’s appeal. BB: Why do you think the book is [...]

Read the full article →

Drug Patent Expirations in October 2010

October 6, 2010

Drug Patent Expirations in October 2010 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ORGARAN Organon Usa Inc danaparoid sodium 5,164,377 Oct 3, 2010 MIRAPEX ER Boehringer Ingelheim pramipexole dihydrochloride 4,886,812 Oct 8, 2010 MIRAPEX Boehringer Ingelheim pramipexole dihydrochloride 4,886,812 Oct 8, 2010 CLIMARA PRO Bayer Hlthcare estradiol; [...]

Read the full article →

Developing a biotechnology cluster in Japan

October 4, 2010

The panel on applying Design Thinking to biotechnology was well received, and I look forward to writing up my observations. I’m now in Japan for a workshop on developing a biotechnology cluster. The U.S. biotechnology industry – the largest in the world – was basically developed with strong support from Japanese pharmaceutical and brewing companies. [...]

Read the full article →

Biotechnology and a Better World by Design

September 28, 2010

I will be moderating a panel on the roles of biotechnology in development at the upcoming A Better World by Design conference at Brown University. The theme of the panel will be the promise and challenges of implementing biotechnology advances for public benefit, with a focus on topics such as disease prevention, agricultural improvements, and [...]

Read the full article →

Medicine for Tomorrow: An Article on Pharmaceutical Research and Development by Nobel Prize-Winning Economist Joseph Stiglitz

September 11, 2010

As stringent new budgets have led to pharmaceutical companies cutting back, a certain concern and scepticism has risen over the high prices charged by drug companies, their continued problems with productivity, and falling success rates of new drugs. A significant drop in investment in drugmaking companies, and president Obama’s recent reforms of the healthcare system [...]

Read the full article →

New reports from DrugPatentWatch

September 10, 2010

New Reports Based on Data-Mining the DrugPatentWatch database Please contact us with any special data requirements beyond the existing report catalog Orphan Drug Report The Orphan Drug Report profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity The Report includes: The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug Details on each [...]

Read the full article →

← Previous Entries

Next Entries →